Climb Bio, Inc. Share Price
NASDAQ: CLYMClimb Bio, Inc. Stock Performance
Open N/A | Prev. Close N/A | Circuit Range N/A |
Day Range N/A | Year Range N/A | Volume N/A |
Average Traded N/A |
Climb Bio, Inc. Share Price Chart
Climb Bio, Inc. Stock Fundamentals & Key Indicators
Market Cap N/A | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $-0.88 | Revenue (TTM) N/A | Return On Equity (TTM) -37.30% |
Profit Margin N/A | Debt to Equity 0.04 | Quarterly Earnings Growth YoY -44.89% |
Climb Bio, Inc. Quarterly Profit & Loss
All figures in USD
Climb Bio, Inc. Annual Profit & Loss
All figures in USD
About Climb Bio, Inc.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|
CLYM Share Price FAQs
What is Climb Bio, Inc. share price today?
What is the 52 week high and 52 week low of Climb Bio, Inc. stock?
What is CLYM's net income for the last quarter?
Can I buy CLYM shares in India?